Summary

Luteinizing hormone and testosterone levels were significantly decreased by treatment with the neurokinin B receptor antagonist AZD4901 80 mg compared with placebo in women with polycystic ovary syndrome. The reductions were maintained throughout the 28 days of treatment. AZD4901 was safe and well tolerated in this group of patients.